Onkológia S5/2024
Current trends in the treatment of metastatic hormone-sensitive prostate cancer – a case report
Introduction: The treatment of metastatic prostate cancer (mHSPC) has undergone remarkable changes in the last decade, which has greatly improved the survival of patients with this disease. Objective: The aim of the article is to briefly summarize the current trends in the treatment of metastatic hormone-sensitive prostate cancer and to point out, on a case from clinical practice, what factors can influence the choice of an appropriate treatment strategy. Patient case: A case report from clinical practice describes a patient with high-risk mHSPC with synchronous metastatic disease. Conclusion: The combination of androgen deprivation therapy (ADT) with novel androgen receptor pathway inhibitors (ARPI) with or without chemotherapy has become the gold standard in the treatment of mHSPC. Local radiotherapy in combination with systemic treatment is also an option for selected patients. However, the choice of a suitable treatment strategy is individual, based on knowledge of risk factors and prognostic subgroups and factors on the part of the patient.
Keywords: metastatic hormone-sensitive prostate cancer, novel androgen receptor pathway inhibitors (ARPI), androgen deprivation therapy
